{
    "id": 13147,
    "fullName": "FGF19 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FGF19 amplification indicates an increased number of copies of the FGF19 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9965,
        "geneSymbol": "FGF19",
        "terms": [
            "FGF19"
        ]
    },
    "variant": "amp",
    "createDate": "10/21/2015",
    "updateDate": "05/08/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10805,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU9931 inhibited Fgfr4 signaling, resulted in growth inhibition of FGF19-amplified hepatocellular carcinoma cell lines in culture, and tumor regression in cell line xenograft models (PMID: 25776529).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 2509,
                "therapyName": "BLU9931",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2415,
                    "pubMedId": 25776529,
                    "title": "First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25776529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11183,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited tumor growth in an FGF19-amplified hepatocellular carcinoma cell line xenograft model (PMID: 28341788).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14977,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB062079 reduced tumor cell growth in patient-derived xenograft models from patients with hepatocellular carcinoma and FGF19 amplification (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1234).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 5832,
                "therapyName": "INCB062079",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11917,
                    "pubMedId": null,
                    "title": "The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/1234.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 inhibited proliferation of FGF19 amplified hepatocellular carcinoma cell lines in culture (PMID: 28978721).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10753,
                    "pubMedId": 28978721,
                    "title": "The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12734,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-6527 inhibited FGFR4 pathway signaling and proliferation and induced apoptosis in an FGF19-amplified hepatocellular carcinoma cell line in culture, and inhibited tumor growth in xenograft models (PMID: 29247039).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10810,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF19-amplified liver cancer cell lines with Klb co-expression were sensitive to BGJ398 in culture (PMID: 23002168).",
            "molecularProfile": {
                "id": 27808,
                "profileName": "FGF19 amp KLB pos"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 872,
                    "pubMedId": 23002168,
                    "title": "FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23002168"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11671,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of FGF3, FGF4, and FGF19 was associated with acquired resistance to combination treatment with Herceptin (trastuzumab) and Tykerb (lapatinib) in an ERBB2 (HER2)-amplified breast cancer cell line xenograft model (PMID: 28381415).",
            "molecularProfile": {
                "id": 28184,
                "profileName": "ERBB2 amp FGF19 amp FGF3 amp FGF4 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9699,
                    "pubMedId": 28381415,
                    "title": "HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28381415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12617,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Votrient (pazopanib) treatment resulted in a partial response that lasted more than 6 months in a patient with bladder papillary urothelial carcinoma harboring FGFR3 S249C, and amplification of FGFR3, FGF19, and CCND1 (PMID: 25766722).",
            "molecularProfile": {
                "id": 28792,
                "profileName": "CCND1 amp FGF19 amp FGFR3 S249C FGFR3 amp"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 5432,
                "name": "bladder papillary transitional cell neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10498,
                    "pubMedId": 25766722,
                    "title": "Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25766722"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13808,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Derazantinib (ARQ 087) treatment resulted in partial response in a patients with FGFR2 and FGF19-amplified urothelial cancer who remained on treatment for 40 weeks (PMID: 28972963; NCT01752920).",
            "molecularProfile": {
                "id": 29430,
                "profileName": "FGF19 amp FGFR2 amp"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11278,
                    "pubMedId": 28972963,
                    "title": "A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28972963"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16228,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, FGF3, FGF4, and FGF19 were coamplified in 90% (8/9) of FGFR1-amplified tumors in patients with ER-positive, ERBB2 (HER2)-negative breast cancer, and the coamplification was associated with resistance to Femara (letrozole) treatment (p=0.0001) (PMID: 28751448).",
            "molecularProfile": {
                "id": 31564,
                "profileName": "ESR1 pos FGF19 amp FGF3 amp FGF4 amp FGFR1 amp"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19464,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 did not inhibit tumor growth in a FGFR4-positive, KLB-negative, and FGF19 amplified and overexpressing patient-derived xenograft (PDX) model of gastric cancer (PMID: 31409633).",
            "molecularProfile": {
                "id": 34161,
                "profileName": "FGF19 amp FGF19 over exp FGFR4 pos KLB neg"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19598,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification, FGFR4 and KLB expression, and FGFR4 V550L demonstrated resistance to treatment with Fisogatinib (BLU-554) (PMID: 31575540).",
            "molecularProfile": {
                "id": 34275,
                "profileName": "FGF19 amp FGFR4 V550L FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19600,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification and FGFR4 and KLB expression demonstrated resistance to treatment with Fisogatinib (BLU-554) and was subsequently found to have acquired FGFR4 C552F (PMID: 31575540).",
            "molecularProfile": {
                "id": 34276,
                "profileName": "FGF19 amp FGFR4 C552F FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19599,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification and FGFR4 and KLB expression demonstrated resistance to treatment with Fisogatinib (BLU-554) and was subsequently found to have acquired FGFR4 V550L (PMID: 31575540).",
            "molecularProfile": {
                "id": 34276,
                "profileName": "FGF19 amp FGFR4 C552F FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19609,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification, FGFR4 and KLB expression, and FGFR4 V550M demonstrated delayed tumor growth when treated with LY2874455 (PMID: 31575540).",
            "molecularProfile": {
                "id": 34277,
                "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19601,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification and FGFR4 and KLB expression demonstrated resistance to treatment with Fisogatinib (BLU-554) and was subsequently found to have acquired FGFR4 V550M (PMID: 31575540).",
            "molecularProfile": {
                "id": 34277,
                "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20155,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in an objective response rate (ORR) of 0% (0/18) and a clinical benefit rate of 11% (2/18) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring 11q13 (containing FGF3, FGF4, FGF19, and CCND1) amplification but not FGFR1 amplification, 11q13 amplification was associated with poor response (7%, 2/29) in biomarker analysis (PMID: 31619444; NCT02053636).",
            "molecularProfile": {
                "id": 34910,
                "profileName": "CCND1 amp FGF19 amp FGF3 amp FGF4 amp"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17719,
                    "pubMedId": 31619444,
                    "title": "Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31619444"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13318,
            "profileName": "FGF19 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 6977,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGF19 amp"
                },
                {
                    "id": 6978,
                    "name": "FGFR4 Inhibitor",
                    "profileName": "FGF19 amp"
                }
            ]
        },
        {
            "id": 27808,
            "profileName": "FGF19 amp KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28184,
            "profileName": "ERBB2 amp FGF19 amp FGF3 amp FGF4 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28792,
            "profileName": "CCND1 amp FGF19 amp FGFR3 S249C FGFR3 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29430,
            "profileName": "FGF19 amp FGFR2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31564,
            "profileName": "ESR1 pos FGF19 amp FGF3 amp FGF4 amp FGFR1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34161,
            "profileName": "FGF19 amp FGF19 over exp FGFR4 pos KLB neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34275,
            "profileName": "FGF19 amp FGFR4 V550L FGFR4 pos KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34276,
            "profileName": "FGF19 amp FGFR4 C552F FGFR4 pos KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34277,
            "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34910,
            "profileName": "CCND1 amp FGF19 amp FGF3 amp FGF4 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}